Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study

Effective management of patients receiving XELOX: Evaluation of impact of dose modifications on outcome in patients from the NO16966, NO16967, and NO16968 trials.

(2017) J. Cassidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials

(2015) D. G. Haller et al.   ANNALS OF ONCOLOGY

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

(2015) Maria Di Bartolomeo et al.   EUROPEAN JOURNAL OF CANCER

Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials

(2015) Matthieu Faron et al.   EUROPEAN JOURNAL OF CANCER

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)

(2015) M. Yoshida et al.   EUROPEAN JOURNAL OF CANCER

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

(2015) Robert J. Mayer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer

(2015) Tsunekazu Mizushima et al.   ONCOLOGY

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)

(2014) M. Yoshida et al.   ANNALS OF ONCOLOGY

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

(2014) D. Papamichael et al.   ANNALS OF ONCOLOGY

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

(2014) Seung Tae Kim et al.   BMC CANCER

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

(2014) J Feliu et al.   BRITISH JOURNAL OF CANCER

A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study

(2014) Hirofumi Yasui et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Refining the Chemotherapy Approach for Older Patients With Colon Cancer

(2014) Nadine J. McCleary et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

Towards improved drugs, combinations and patient selection

(2014) Hans-Joachim Schmoll et al.   Nature Reviews Clinical Oncology

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

(2014) Fotios Loupakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database

(2013) Nadine J. McCleary et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

(2013) David Cunningham et al.   LANCET ONCOLOGY

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

(2012) Dimitrios Pectasides et al.   BMC CANCER

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

(2011) C. Twelves et al.   ANNALS OF ONCOLOGY

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

(2011) S Stintzing et al.   BRITISH JOURNAL OF CANCER

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

(2011) Matthew T Seymour et al.   LANCET

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

(2010) Niall C. Tebbutt et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

(2009) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

(2009) E Vasile et al.   BRITISH JOURNAL OF CANCER

Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

(2009) M. Kozloff et al.   ONCOLOGIST

Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials

(2008) Hendrik-Tobias Arkenau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY